Understand the source comparison
ARA-290 Safe Side Effects: Comparison to Related Compounds
ARA-290 Selective IRR agonist (EPOR/CD131 heterodimer) Injection site reactions (6%), mild nausea (4%), transient headache (3%) None—does not activate erythropoiesis Cleanest safety profile among EPO derivatives; limited long-term data but favorable short-term
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA-290
- Selective IRR agonist (EPOR/CD131 heterodimer)
- Injection site reactions (6%), mild nausea (4%), transient headache (3%)
- None—does not activate erythropoiesis
- Cleanest safety profile among EPO derivatives; limited long-term data but favorable short-term tolerability
- Erythropoietin (EPO)
- Full EPOR agonist (homodimer + heterodimer)
- Hypertension (20–30%), thrombosis (5–8%), flu-like symptoms (15%)
- Elevated hematocrit, increased clotting risk
- Higher efficacy for anemia but carries cardiovascular burden; requires hematocrit monitoring
- BPC-157
- Growth factor signaling (exact receptors unclear)
- Minimal—occasional GI upset (<5%)
- None documented
- Broader tissue repair claims but less mechanistic clarity; safety data mostly preclinical
- Thymalin
- Thymic peptide complex (immune modulation)
- Rare allergic reactions (<2%), injection site inflammation
- None
- Immunomodulatory rather than tissue-protective; different safety concerns (autoimmune flare potential)
- Cerebrolysin
- Neurotrophic peptide mixture
- Dizziness (10%), agitation (6%), injection site pain (8%)
- Neurotrophic focus; CNS-related side effects more common than with ARA-290